Ascendis Pharma AS (ASND)
124.12
-2.43
(-1.92%)
USD |
NASDAQ |
Nov 08, 16:00
124.12
0.00 (0.00%)
After-Hours: 16:58
Ascendis Pharma Revenue (TTM): 343.51M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 343.51M |
March 31, 2024 | 356.43M |
December 31, 2023 | 288.35M |
September 30, 2023 | 163.47M |
June 30, 2023 | 126.57M |
March 31, 2023 | 81.45M |
December 31, 2022 | 53.04M |
September 30, 2022 | 35.23M |
June 30, 2022 | 21.14M |
March 31, 2022 | 15.81M |
December 31, 2021 | 9.044M |
September 30, 2021 | 4.081M |
June 30, 2021 | 5.993M |
March 31, 2021 | 6.342M |
December 31, 2020 | 7.899M |
September 30, 2020 | 10.04M |
June 30, 2020 | 9.307M |
March 31, 2020 | 11.33M |
December 31, 2019 | 15.03M |
September 30, 2019 | 24.25M |
Date | Value |
---|---|
June 30, 2019 | 21.78M |
March 31, 2019 | 18.19M |
December 31, 2018 | 12.08M |
September 30, 2018 | 0.4089M |
June 30, 2018 | 0.8958M |
March 31, 2018 | 1.363M |
December 31, 2017 | 1.725M |
September 30, 2017 | 2.520M |
June 30, 2017 | 3.315M |
March 31, 2017 | 4.110M |
December 31, 2016 | 5.101M |
September 30, 2016 | 6.139M |
June 30, 2016 | 7.187M |
March 31, 2016 | 8.051M |
December 31, 2015 | 9.011M |
September 30, 2015 | 10.38M |
June 30, 2015 | 12.33M |
March 31, 2015 | 15.55M |
December 31, 2014 | 18.68M |
September 30, 2014 | 22.71M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
4.081M
Minimum
Sep 2021
356.43M
Maximum
Mar 2024
82.32M
Average
15.81M
Median
Mar 2022
Revenue (TTM) Benchmarks
Evaxion Biotech AS | 3.295M |
Adaptimmune Therapeutics PLC | 141.46M |
Biodexa Pharmaceuticals PLC | -- |
NuCana PLC | -- |
Genfit SA | 30.01M |